Low-intensity low-frequency pulsed ultrasound ameliorates sciatic nerve dysfunction in a rat model of cisplatin-induced peripheral neuropathy

Busra Bilir-Yildiz¹, Fatma Bahar Sunay², Hatice Fulya Yilmaz¹ & Ozlem Bozkurt-Girit¹*

Chemotherapy-induced peripheral neuropathy is a neurological complication that frequently occurs during chemotherapeutic intervention, resulting in damaged myelin sheath, motor weakness and/or sensory impairment. This study aims to investigate the therapeutic efficiency of low-intensity pulsed low-frequency ultrasound on cisplatin-induced peripheral neuropathy. Rats were randomly divided into five experimental groups as control, cisplatin administration, 10 mg/kg melatonin treatment after cisplatin administration, 1 MHz frequency 0.5 W/cm² pulsed ultrasound treatment after cisplatin administration and 1 MHz frequency 1.5 W/cm² pulsed ultrasound treatment after cisplatin administration. Chemical neuropathy was induced by the injection of 3 mg/kg/week of cisplatin (i.p.) for 5 weeks. Afterwards, melatonin and pulsed ultrasound treatments were applied for 15 consecutive days. Cisplatin administration resulted in a decrease in nociceptive pain perception and nerve conduction velocities together with a decrease in myelin thickness and diameters of axons and myelinated fibers, indicating a dysfunction and degeneration in sciatic nerves. In addition, cisplatin administration led to a decrease, in superoxide dismutase activity, and an increase in malondialdehyde and IL-1β levels together with an increase in caspase-3 protein expression levels and a decrease in Bcl-2 and Parkin levels. The ultrasound treatments resulted in an increase in nociceptive pain perception and sciatic nerve conduction; led to a decrease in oxidative stress and inflammation, restored nerve degeneration and regulated apoptosis and mitophagy. Taken together, low-intensity pulsed low-frequency ultrasound was efficient in restoring the alterations attributable to cisplatin-induced peripheral neuropathy, and warrants further investigations.

Peripheral neuropathy can be defined as the deterioration of the structure of peripheral nerves that results in the loss of deep tendon reflex, sensory nerve dysfunction, motor and muscle weakness¹. Damage to the involved nerves may manifest mainly in the form of axonal degeneration, segmental demyelination, or a combination of both. In addition, peripheral neuropathy may result in excessive myelin loss and eventually loss of axons². There are a number of factors that can lead to peripheral neuropathy including diabetes, inherited diseases, poor nutrition, certain medications and chemotherapeutic agents³. The type of peripheral neuropathy is named as chemotherapy-induced neuropathy when the damage is caused by the exposure of toxic chemotherapeutic agents.

Cisplatin is the first synthesized molecule among platinum-based anti-cancer drugs and is one of the most important antineoplastic drugs used in cancer treatment. It is used in the treatment of solid tumors, such as lung, testis, head, neck, bladder and kidney cancers and lymphoma with hematological cancer⁴. Cisplatin interacts with DNA, causing cross-linking in the chain and creating openings in the DNA helix, thus preventing cell proliferation and demonstrating cytotoxic effect on tumors and rapidly dividing cancerous cells⁵–⁷.

Cisplatin-induced peripheral neuropathy usually appears with axonal damage, which manifests itself after a period following cisplatin administration⁸. It has been reported in many studies that neuropathy induced either by chemotherapy or any other factors causes a decrease in mitochondrial function due to increased reactive

¹Department of Biophysics, School of Medicine, Aydın Adnan Menderes University, Aydın 09010, Turkey. ²Department of Histology and Embryology, School of Medicine, Balıkesir University, Balıkesir, Turkey. *email: ozlem.bozkurt@adu.edu.tr
oxygen species and oxidative stress in nerve cells. Moreover, recent scientific advances have implicated that the molecular mechanism of neurodegeneration and neuropathy may be related to the inhibition of autophagy and mitophagy leading to the accumulation of oxidant damage in proteins and organelles. Therefore, methods to regulate autophagy or mitophagy were suggested to play an important role in the treatment of peripheral neuropathy by the reduction of nerve damage.

It has been suggested that ultrasound (US) has a therapeutic effect in tissue repair processes by stimulating cell proliferation and differentiation. Indeed, low-intensity pulsed US has become a routine practice in the treatment of pseudoarthrosis, bone fractures and soft tissue healing. Recently, Wang et al. showed that low-intensity pulsed US promotes chondrogenesis by regulating autophagy in mesenchymal stem cells. Low-intensity pulsed US application was reported to accelerate nerve regeneration in animal models of peripheral nerve injury, increasing the proliferation of human and animal Schwann cells, and enhancing various gene and protein expressions of neural race. However, the responses obtained with the US treatment vary depending on the power density, frequency, and duration of the US. There is no consensus on the values of these parameters in the reported studies in the literature. In addition, the efficacy of US treatment in chemotherapy-induced peripheral neuropathy has not yet been investigated. Accordingly, this study was conducted to assess the efficacy of low-intensity pulsed low-frequency US in the treatment of cisplatin-induced peripheral neuropathy in rats.

Table 1. Results of the nociceptive tests recorded as latency (s) of a reaction given in response to thermal painful stimuli during the 5-week period of chemical neuropathy induction. The data were represented as mean ± standard error of mean. Differences in between variances were compared by One-way ANOVA test with Tukey’s test applied as a post-hoc test. P-values equal or less than 0.05 were considered as statistically significant (*p < 0.05, **p < 0.01, ***p < 0.001). The degree of significance was symbolized with asterisks (*) for the comparisons to that of control group (C).

| Nociceptive test results | Latency (s) | 1st week | 3rd week | 5th week |
|--------------------------|------------|----------|----------|----------|
| Hot Plate                | Groups     |          |          |          |
| C                        | 4.33 ± 0.18| 3.57 ± 0.16| 4.19 ± 0.11|
| CP                       | 5.26 ± 0.09**| 5.68 ± 0.10**| 5.62 ± 0.08***|
| Tail Flick               | Groups     |          |          |          |
| C                        | 4.99 ± 0.11| 4.57 ± 0.17| 4.75 ± 0.13|
| CP                       | 6.06 ± 0.09**| 6.19 ± 0.08***| 6.26 ± 0.07***|

#### Results

**Nociceptive pain perception.** Figure 1 demonstrates the timing of the applied experimental procedures. According to the nociceptive test results, during the 5-week period of cisplatin injection, there was a considerable increase in the latencies of the reactions given in response to thermal painful stimuli in comparison to the control group (Table 1), which revealed the decreased pain perception upon cisplatin administration. All treatments resulted in a significant decrease in nociceptive hot plate and tail flick latencies (p < 0.05) in comparison to the cisplatin-induced neuropathy group by the end of the treatment period (Table 2).

**Electrophysiological recordings.** Table 3 demonstrates the alterations in the motor nerve conduction velocities, distal latencies, peak-to-peak amplitude, area and duration of the compound muscle action potential (CMAP) recordings of all experimental groups. As can be seen from Table 3, cisplatin administration led to a significant decrease in motor nerve conduction velocities (MNCV) in comparison to that of the control group (p < 0.001). The treatments resulted in an increase in sciatic MNCV in comparison to that of cisplatin-induced neuropathy group (p < 0.05). In addition, there was a significant decrease in the amplitudes of the CMAP recordings (p < 0.01) of cisplatin administered group compared to the control group (Table 3). This finding demonstrated the presence of axonal damage in cisplatin-induced neuropathy group, as axonal damage and demyelination...
Elimination results in the decrease in amplitude values in CMAP recordings. The duration of the recorded CMAP was observed to slightly increase in the cisplatin-induced neuropathy group, whereas it was significantly decreased in the US treatment groups ($p < 0.05$).

**Western blot analysis.** The expression levels of Bcl-2 and caspase-3 proteins in the sciatic nerve tissue homogenates were determined to provide information about the activation of apoptotic pathway, and the expression level of Parkin protein was examined to provide information about the induction of mitophagy. The obtained results were analyzed in comparison to that of β-actin. As seen in Fig. 2a, the expression level of Bcl-2/β-actin was significantly decreased in the cisplatin administered group compared to the control group ($p < 0.05$), whereas a significant increase in Bcl-2 expression level was observed in melatonin, 1 MHz 0.5 W/cm² US and 1 MHz 1.5 W/cm² US treatment groups compared to the control group and cisplatin group ($p < 0.05$). The increase was more pronounced in US-treated groups, especially in the 1 MHz 1.5 W/cm² US treatment group.

Figure 2b shows the alterations in the caspase-3/β-actin protein expression levels in sciatic nerves. As can be seen from the figure, the level of caspase-3 protein was significantly higher in cisplatin administered group in comparison to that of control ($p < 0.01$). Upon treatments, the level of caspase-3 was significantly decreased ($p < 0.05$) in comparison to cisplatin administered group, where the decrease in the caspase-3 expression level

### Table 2. Results of the nociceptive tests recorded as latency (s) of a reaction given in response to thermal painful stimuli during the 15-day treatment period. The data were represented as mean ± standard error of mean. Differences in between variances were compared by One-way ANOVA test with Tukey's test applied as a post-hoc test. $P$-values equal or less than 0.05 were considered as statistically significant (*$p < 0.05$, **$p < 0.01$, ***$p < 0.001$). The degree of significance was symbolized by an asterisks (*) for the comparison of all groups with respect to the control group; by a double daggers (‡) for the comparison of the treatment groups with respect to the cisplatin administered group; by a daggers (†) for the comparison of ultrasound treated groups with respect to the melatonin administered group and by a section ($) for the comparison of 1 MHz 1.5 W/cm² US treated group with respect to the 1 MHz 0.5 W/cm² US treated group.

| Nociceptive Tests | Groups          | Latency (s) Before treatment | Mid-treatment | End of treatment |
|-------------------|-----------------|-----------------------------|---------------|-----------------|
| Hot-plate         | C               | 4.60 ± 0.18                 | 4.83 ± 0.17   | 4.86 ± 0.15     |
|                   | CP              | 5.97 ± 0.18                 | 5.86 ± 0.21   | 5.81 ± 0.11     |
|                   | CP + MEL        | 5.10 ± 0.14                 | 4.21 ± 0.11   | 4.01 ± 0.09     |
|                   | CP + US (0.5 W/cm²) | 5.33 ± 0.21         | 3.97 ± 0.16   | 3.64 ± 0.10     |
|                   | CP + US (1.5 W/cm²) | 5.20 ± 0.16            | 3.96 ± 0.16   | 3.21 ± 0.17     |
| Tail-flick        | C               | 4.87 ± 0.12                 | 4.45 ± 0.25   | 4.90 ± 0.12     |
|                   | CP              | 6.57 ± 0.15                 | 6.72 ± 0.29   | 7.25 ± 0.48     |
|                   | CP + MEL        | 6.23 ± 0.15                 | 4.18 ± 0.21   | 3.88 ± 0.10     |
|                   | CP + US (0.5 W/cm²) | 6.24 ± 0.22            | 3.81 ± 0.24   | 3.72 ± 0.19     |
|                   | CP + US (1.5 W/cm²) | 5.88 ± 0.21             | 3.69 ± 0.17   | 3.42 ± 0.16     |

### Table 3. The results of the alterations in distal latency, peak-to-peak amplitude, area and duration of the compound muscle action potential recordings, and the sciatic motor nerve conduction velocities in the experimental study groups. The data were represented as mean ± standard error of mean. Differences in between variances were compared by One-way ANOVA test with Tukey's test applied as a post-hoc test. $P$-values equal or less than 0.05 were considered as statistically significant (*$p < 0.05$, **$p < 0.01$, ***$p < 0.001$). The degree of significance was symbolized by an asterisks (*) for the comparison of all groups with respect to the control group; by a double daggers (‡) for the comparison of the treatment groups with respect to the cisplatin administered group; by a daggers (†) for the comparison of ultrasound treated groups with respect to the melatonin administered group and by a section ($) for the comparison of 1 MHz 1.5 W/cm² US treated group with respect to the 1 MHz 0.5 W/cm² US treated group.

| Electrophysiological measurements | Groups          | C                | CP                        | CP + MEL                   | CP + US (0.5 W/cm²) | CP + US (1.5 W/cm²) |
|----------------------------------|-----------------|-----------------|--------------------------|---------------------------|---------------------|--------------------|
| Motor nerve conduction velocity (m/s) | 76.65 ± 0.43 | 38.07 ± 0.32*** | 54.92 ± 0.24**          | 51.98 ± 0.12**          | 50.25 ± 0.14**     |
| Distal latency (s)               | 0.0025 ± 0.0010 | 0.0030 ± 0.0011 | 0.0023 ± 0.0020          | 0.0022 ± 0.0013          | 0.0022 ± 0.0010    |
| Amplitude (peak-to-peak) (mV)    | 10.18 ± 0.23    | 3.91 ± 0.39**   | 5.46 ± 0.21              | 6.57 ± 0.10†             | 7.19 ± 0.33†       |
| Area (mV.ms)                     | 0.0027 ± 0.0004 | 0.0020 ± 0.0001 | 0.0017 ± 0.0001          | 0.00016 ± 0.0002         | 0.00017 ± 0.0001   |
| Duration (ms)                    | 1.02 ± 0.22     | 1.86 ± 0.24     | 0.87 ± 0.05              | 0.70 ± 0.06**            | 0.66 ± 0.09**      |
was significantly lower in 1 MHz 0.5 W/cm² US treatment group \( (p<0.05) \) in comparison to that of melatonin administration.

Figure 2c shows the protein expression levels of Parkin/β-actin in the experimental groups. Parkin is a protein that takes role in the ubiquitination of mitochondrial outer membrane proteins and is known to play an important role in the destruction of the damaged mitochondria; therefore, gives information about the induction of mitophagy. As can be seen in Fig. 2c, the expression level of Parkin protein was significantly decreased in cisplatin administered group \( (p<0.05) \) in comparison to that of control. The levels of Parkin protein were...
observed to be similar to that of cisplatin administered group in 1 MHz 0.5 W/cm² US treated group; however, there was a significant increase in Parkin protein expression level in melatonin administered and 1 MHz 1.5 W/cm² US treatment group (\(p < 0.05\)) in comparison to that of cisplatin administered group. This finding implies that 1 MHz 1.5 W/cm² US treatment led to an improvement in the induction of mitophagy.

Biochemical results. Figure 3a demonstrates the malondialdehyde (MDA) levels and superoxide dismutase (SOD) activity in sciatic nerves. The amount of MDA, a product of lipid peroxidation, was observed to be increased in nerve homogenates of cisplatin-induced neuropathy group (\(p < 0.01\)) in comparison to that of control, which indicates the increase in oxidative stress²⁰. Upon treatments, MDA levels were observed to be significantly decreased in comparison to that of cisplatin administered group (\(p < 0.05\)). In addition, the activity of SOD was observed to be significantly decreased in cisplatin administered group (\(p < 0.001\)), which was noted to be significantly increased in treatment groups in comparison to that of cisplatin administered group (\(p < 0.05\)). Increase in SOD activity in treatment groups indicated a decreased oxidative stress²⁰, which is in accordance with the finding of decreased MDA levels in treatment groups.

In order to comment on the effect of treatments on inflammation, the levels of pro-inflammatory cytokines interleukin-1 beta (IL-1β) and interleukin-6 (IL-6) in serum samples of the experimental groups were assessed. As seen in Fig. 3b, there was a slightly higher content of IL-1β and IL-6 in the cisplatin administered group compared to the control group, although the increase was statistically insignificant. In the US treatment groups, the
levels of these cytokines were observed to be decreased compared to the cisplatin administered group, where the decrease was more prominent in the US treatment groups ($p < 0.05$). IL-1β and IL-6, which are pro-inflammatory cytokines, are involved in the formation of inflammatory changes and the emergence of a rapid immune response. The results revealed that an immune response emerged in the cisplatin induced neuropathy group, which was ameliorated upon US treatments.

**Histological analysis.** Figure 4 demonstrates the representative images of hematoxylin–eosin, Masson's trichrome and luxol fast blue (LFB) stained sciatic nerve sections belonging to the study groups. LFB staining was used to visualize myelin/myelinated axons in nerve sections. Masson's trichrome stain was used for the visualization of the connective tissue component of the nerve and general histological changes, and to comment on the degree of degeneration in nerve sections. In the sciatic nerve sections of the control group, the nerve fibers had a normal appearance and the nerve fiber myelination was also at normal levels. However, focal areas of demyelination and degenerative changes in nerve fibers were detected in cisplatin administered group.
Upon treatments, the areas of demyelination and degeneration were observed to be decreased. The LFB stained images were further analyzed using ImageJ program to calculate the axon diameter, myelin sheath thickness and myelinated fiber diameter in the experimental groups (Table 4). There was a significant decrease in myelin sheath thickness (p < 0.01) together with a significant decrease in axon diameter (p < 0.01) and myelinated fiber diameter (p < 0.001) in cisplatin administered group in comparison to that of control. Treatments, more prominently the US treatments, led to an increase in these calculated parameters (Table 4). Especially in the 1.5 W/cm² US treated group with respect to the 1 MHz 0.5 W/cm² US treated group.

### Discussion

The present study was conducted to assess the therapeutic effects of low-intensity pulsed low-frequency US applied at two different power intensities on a rat model of cisplatin-induced neuropathy. Peripheral neuropathy induced by the administration of chemotherapeutic agents is a complication that frequently occurs in chemotherapy intervention. Platinum compounds (cisplatin, carboplatin, oxaliplatin) belonging to the class of neurotoxic chemotherapy agents are associated with neuropathy. The symptoms progress to more proximal regions as the taken dose amount increases cumulatively or the duration of neuropathy can be affected. Therefore, animal models of agent-induced neuropathy have been used to advance treatment alternatives that can be applied to prevent or minimize nerve damage or the duration of neuropathy can be affected. Therefore, animal models of agent-induced neuropathy have been used to advance treatment alternatives that can be applied to prevent or minimize nerve damage24,25. Cisplatin is one of the most widely used drugs to treat various cancers and is highly effective due to its cytotoxic nature, cisplatin binds to nuclear DNA and activates some signaling pathways by disrupting DNA transcription and replication27. The rats in the current study received a weekly dose of 3 mg/kg i.p. injection of cisplatin for five weeks (a cumulative dose of 15 mg/kg cisplatin). This regime was chosen as it was previously reported to yield a cisplatin-induced neuropathy24,28,29 with a better clinical status of rats, and in addition, in order to create a similar course of administration as it is in human subjects.

Regardless of the advanced diagnosis and surgical treatments, patients receiving chemotherapy intervention may encounter permanent or sustained nerve damage. Although therapeutic US has a wide range of application areas in medicine and numerous studies reported the effects of US in nerve regeneration and growth in nerve injuries; only a few studies have been performed to examine the role of US in treatment of peripheral neuropathy. Previously, Daeschler et al. have reported that US therapy between 200 and 500 mW/cm² applied after nerve injury significantly accelerated axonal regeneration and re-innervation of the muscle in nerve injury model, increased the number and myelination of distant axons to the lesion site, and improved nerve conduction velocity in the lowest intensity range of 200–300 mW/cm²20. Two studies in literature have compared the effects of low-level laser therapy and low-frequency (1 MHz) low-intensity US application in a pulsed mode in type-2 diabetic patients with carpal tunnel syndrome24 and in a continuous mode in patients with ulnar neuropathy at the elbow, at 1 W/cm² and 1.5 W/cm² power intensities, respectively. Both of these studies have reported the beneficial effects of US application on clinical and electrophysiological parameters; however, no data to elucidate the mechanism of action of low-intensity US treatment in neuropathy were reported. In this current study, the results revealed the effectiveness of 1 MHz 0.5 and 1.5 W/cm² pulsed US treatment on the repair of the nerve damage caused by cisplatin-induced neuropathy, and our findings are important for the further clinical application of US therapy and clarification of its mechanisms. Peripheral neuropathy was reported to result in pathologic changes in the nerve, loss of deep tendon reflex, motor weakness, loss of myelinated fibers and decreased myelinated axon diameter². Indeed, the results of this current study revealed a decrease in motor nerve conduction velocity together with histological changes in sciatic nerves, such as a decrease in myelin sheet thickness, myelinated fiber and axon diameters in cisplatin-induced neuropathy. Moreover, the decrease in CMAP amplitudes together with the slightly prolonged distal latency and CMAP duration may further indicate the axonal loss, damage and demyelination in sciatic nerves upon cisplatin administration. There was also a decrease in nociceptive pain perception in cisplatin administered group; therefore, the results of this study revealed a decrease in nerve function upon cisplatin administration. Low-intensity pulsed low-frequency US treatment applied at 0.5 and 1.5 W/cm² power intensities significantly improved the nerve conduction velocities, CMAP amplitudes and decreased CMAP duration values together with nociceptive latencies. These findings are in accordance with the literature, as there are studies reporting the beneficial effects of US stimulation to increase nerve conduction velocities, CMAP amplitude and area in nerve injury models. Savernini et al. have stated that

| Measurements (μm) | Groups | C | CP | CP + MEL | CP + US (0.5 W/cm²) | CP + US (1.5 W/cm²) |
|------------------|-------|----|----|---------|---------------------|---------------------|
| Myelinated fiber diameter | 2.64 ± 0.01 | 1.76 ± 0.01*** | 1.87 ± 0.02*** | 2.29 ± 0.01** | 2.35 ± 0.01*** |
| Myelinated fiber diameter | 0.60 ± 0.00 | 0.37 ± 0.00** | 0.42 ± 0.00** | 0.46 ± 0.00† | 0.53 ± 0.00† |
| Axon diameter | 2.14 ± 0.01 | 1.60 ± 0.01** | 1.78 ± 0.02 | 1.96 ± 0.01** | 2.03 ± 0.01*** |

Table 4. The results of the alterations in axon diameter, myelin sheet thickness and myelinated fiber diameter in the experimental study groups. The data were represented as mean ± standard error of mean. Differences in between variances were compared by One-way ANOVA test with Tukey’s test applied as a post-hoc test. P-values equal or less than 0.05 were considered as statistically significant (*p < 0.05, **p < 0.01, ***p < 0.001). The degree of significance was symbolized by an asterisks (*) for the comparison of all groups with respect to the control group; by a double daggers (‡) for the comparison of the treatment groups with respect to the cisplatin administered group; by a daggers (†) for the comparison of ultrasound treated groups with respect to the melatonin administered group and by a section ($) for the comparison of 1 MHz 1.5 W/cm² US treated group with respect to the 1 MHz 0.5 W/cm² US treated group.
the application of 0.3 and 0.4 W/cm² therapeutic US led to the decrease in hyperalgesia induced by the chronic constriction injury on the infraorbital nerve of rats. However, they have reported that therapeutic ultrasound did not alter the thermonecrotic threshold of sham and naive rats; therefore, they have suggested that the anti-nociceptive effects of therapeutic US could be triggered through the stimulation of macrophages and mast cells to secrete mediators in nerve injury. Similarly, Chen et al. have observed that low-intensity pulsed US treatment attenuated lipopolysaccharide-induced neuroinflammation in the cortex and hippocampus of a mice model of neuroinflammation and memory impairment. However, their results revealed that low-intensity US treatment resulted in dissimilar alterations when applied on sham or lipopolysaccharide-treated mice, suggesting that the action of ultrasound may differ when there is an inflammatory stimulus present in the system. Supporting this notion, 0.5 W/cm² US was reported to be sufficient to accelerate peripheral nerve regeneration in crush injury and the damaged nerve was reported to be more sensitive to US than the intact nerve. In addition, in the current study, histological examinations revealed that myelin sheath thickness together with axon and myelinated fiber diameter was increased upon the US treatments in both power intensities. Therefore, low-intensity pulsed low-frequency US treatment ameliorated the nerve dysfunction observed in cisplatin administration, and the increase in nerve conduction velocity may be associated with apparent axonal healing.

Nerve dysfunction in peripheral neuropathy is known to be associated with oxidative stress and neuro-inflammation. Peripheral nerves are susceptible to oxidative stress, which results in lipid peroxidation, neuroinflammation and damage to the myelin sheath due to weak cellular antioxidant defenses. The results of the current study revealed the increase in pro-inflammatory cytokines and oxidative stress as a result of cisplatin administration, which were observed to be decreased upon US treatments. Nerve injuries result in the rapid production and secretion of pro-inflammatory cytokines, but their levels start to attenuate approximately after 7 days, and their anti-inflammatory cytokines are predominantly released. However, Ruohonen et al. have demonstrated the prolonged inflammatory mediator changes taking place in the sciatic nerve, and have observed a marked increase in the expression of IL-1β levels in the epi-/perineurium and endoneurium 14 days after the injury together with the increase in number of macrophages in these regions. Their findings support the observed increase in IL-1β levels observed in this current study upon cisplatin administration. Low-intensity pulsed US has been suggested to play a protective role in neuroinflammation by decreasing the expression levels of pro-inflammatory cytokines in the cortex of lipopolysaccharide (LPS)-treated mice model of neuroinflammation and memory impairment, and in LPS-treated microglial cells through the modulation of toll-like receptor 4 (TLR4)/ nuclear factor kappa B (NF-kB) signaling. In addition, low-intensity focused US was reported to improve cerebral blood flow and to reduce neuroinflammation and pro-inflammatory cytokine levels by the inhibition of TLR4/NF-kB pathway in the medial prefrontal cortex of a rat model of vascular dementia. Furthermore, Ito et al. have demonstrated that 1 MHz 140 mW/cm² US stimulation led to a decrease in the gene expression levels of pro-inflammatory cytokines in sciatic nerves of a rat crush injury model. They have suggested that US stimulation facilitated Wallerian degeneration, which in turn promoted early nerve regeneration, through the modulation of the levels of pro-inflammatory cytokines. Therefore, the observed beneficial effects of low-intensity pulsed low-frequency US treatment on the improvement of sciatic nerve conduction might be related to the decrease in neuroinflammation, which was previously reported to increase the survivability of the neurons and synaptic functions. However, the effects of US treatment on the levels of inflammatory cytokines together with the related signaling pathways needs further validation in future studies.

Oxidative stress and inflammation have important effects on organelle function. Nowadays, especially inflammation or an ongoing inflammation is thought to be the main cause of many diseases. Increased oxidative stress causes damage to proteins and organelles, especially to the mitochondria. In addition, oxidative stress and increased inflammation may cause the activation of apoptotic or mitophagic pathways. Members of the Bcl-2 family, consisting of pro-apoptotic and anti-apoptotic proteins, contribute to the survival or death of cells. Disruption of the balance created by the members of Bcl-2 family facilitates the release of cytotoxic factors from the mitochondria and leads to the activation of apoptosis. Likewise, the impairment of calcium release or improper processing of proteins within the endoplasmic reticulum can lead to induction of apoptotic cell death. Caspases, which are cysteine proteases, play a role in the course of apoptosis. In order for apoptosis to start in the cell, caspase-3 protein must be activated by the cleavage of procaspase-3, which in turn triggers apoptosis. Stimulation of apoptosis causes fewer side effects and is a preferred immune system cell death method. In the current study, the expression level of uncleaved caspase-3 was observed to be increased in the cisplatin administered group and was decreased upon treatments, especially in the US treatment groups. In addition, the amount of anti-apoptotic Bcl-2 protein expression was significantly reduced upon cisplatin administration, which was increased to that of control levels by the treatments. Cisplatin was previously reported to induce apoptosis in neuronal cells and overexpression of Bcl-2 was shown to block cisplatin-induced apoptosis in a rat neuroblastoma cell line. Therefore, the observed increase in pro-caspase-3 together with the decrease in anti-apoptotic Bcl-2 protein levels may indicate the apoptotic activation upon cisplatin administration. The low-intensity pulsed low-frequency US treatments in both power intensities restored the levels of these proteins, revealing that US treatment played a role in the regulation of apoptosis in sciatic nerves and suppressed apoptosis.

Pathological diseases such as inflammation, cancer, neuropathic and neurodegenerative diseases have been associated with mitophagy disorders. Parkin, the signal protein specific to mitophagy, can initiate the commissioning of the autophagy mechanism and facilitate the ingestion of damaged mitochondria into autophagosomes. Therefore, the increase in the Parkin level is an indication for the activation of mitophagy pathway, which can be an effective mechanism to eliminate the damaged mitochondria. However, incomplete mitophagy is also harmful, as the neurons rely on mitochondrial respiration and the effects of deprived mitochondria cannot be diluted by cell division. As a result, damage to the mitochondria and other cellular components leads to constant disruption in neuronal functions and peripheral neuropathy. For this reason, the decrease in Parkin levels observed in the cisplatin administered group in our study implied that the mitochondria damaged...
by oxidative stress may not be cleared sufficiently with mitophagy in cisplatin administration. However, the observed increase in Parkin levels in the 1.5 W/cm² US group indicated that US treatment can regulate mitophagy and therefore it can be an important alternative in the elimination of nerve damage by the regulation of intracellular apoptotic and mitophagic pathways.

Melatonin was previously demonstrated to decrease lipid peroxidation, axonal injury and myelin breakdown in crush injuries³⁴, prevent mitochondrial dysfunction and promote neuroprotection in oxaliplatin-induced neuropathy³⁶ and in paclitaxel-induced neuropathic pain models³⁵. Therefore, in this current study, melatonin administration was chosen as a positive control in order to compare the results of US treatments. In all of the parameters investigated, melatonin and US treatments yielded similar results. However, low-intensity pulsed low-frequency US treatment was observed to be more effective especially in activating mitophagy, suppressing apoptosis, decreasing inflammation and reducing demyelination and nerve degeneration after cisplatin administration.

Taken together, low-intensity pulsed low-frequency US treatment ameliorated the nerve dysfunction in cisplatin-induced peripheral neuropathy by decreasing oxidative stress and inflammation, regulating apoptosis and mitophagy, reducing demyelination and nerve degeneration, thereby increasing motor nerve conduction and nociceptive pain perception. However, there are some limitations of this study. The major limitation is that the levels of only two pro-inflammatory markers and the expression levels of only one protein in the apoptosis and mitophagy pathways were considered. Therefore, the role of US treatment particularly in modulating apoptosis, mitophagy and mitochondrial dysfunction as well as inflammatory pathways, as implied by the results of the current study, should be more clearly addressed in future studies. In this study, the alterations in the expression level of uncleaved caspase 3 were evaluated, however, in order to better comment on the modulation of apoptosis upon US stimulation, the expression levels of cleaved caspase 3 together with other caspases in the cascade should be assessed in future studies. The levels of pro-inflammatory cytokines were measured using ELISA tests, which might have given less sensitive results; therefore, the alterations in inflammatory markers should be determined in future studies using more sensitive techniques. In addition, US applied control groups were not included in the study, which prevented the consistent comparison of the effects of US treatments, especially in the interpretation of the results of nociceptive latencies and levels of pro-inflammatory cytokines. Consequently, low-intensity pulsed low-frequency US therapy can be considered as an alternative strategy for the treatment of chemotherapy-induced neuropathies and warrants further investigations.

Materials and methods

Animals. All experimental procedures used in this study were approved by the Ethics Committee of Aydın Adnan Menderes University with an approval number 64583101/2019/012 and were performed in accordance with the ARRIVE guidelines. All experimental methods were performed in accordance with relevant guidelines and regulations. Adult male Wistar-albino rats (n = 50) weighing 300–350 g were kept in an environment temperature of 22 ± 1°C, 12/12 h of light/dark cycle, relative humidity (40–50%) and air conditioning controlled semi-climatized laboratory conditions. The rats were randomly divided into 5 experimental groups (10 animals in each group) as control (C), cisplatin administration (CP), 10 mg/kg melatonin treatment (CP + MEL), 1 MHz frequency 0.5 W/cm² pulsed US treatment (CP + US 0.5 W/cm²) and 1 MHz frequency 1.5 W/cm² pulsed US treatment (CP + US 1.5 W/cm²) groups. The rats in the control group only received vehicle and the rats in the other groups were administered with 3 mg/kg cisplatin injection once a week for a 5-week period for the induction of chemical neuropathy. Afterwards, melatonin and low-intensity pulsed low-frequency US treatments were performed for 15 consecutive days (Fig. 1).

Drugs and their administration. In order to achieve a rat model of cisplatin-induced neuropathy, cisplatin (Item no: 13119, Cayman Chemical, Michigan, USA) was dissolved in saline and was intraperitoneally (i.p.) administrated at the dose of 3 mg/kg once a week for five weeks (total cumulative dose is 15 mg/kg), as previously reported in the literature³⁴,³⁵,³⁶. In order to prevent kidney injury due to cisplatin injection, the calculated dose was mixed with 2 ml of physiological saline prior to injection. Melatonin (Item no: 14427, Cayman Chemical, Michigan, USA) was dissolved in 5% ethanol and was administered to the rats in CP + MEL group intraperitoneally at a dose of 10 mg/kg/day for 15 consecutive days.

Low-intensity pulsed low-frequency US treatment. Low-intensity pulsed low-frequency US was applied to the rats with cisplatin-induced chemical neuropathy by BTL5710 SONO US device (BTL Medical Technologies, Czechia). The rats were restrained in prone position and their head was covered with a cloth, enabling them to keep the same position for 3 min. The US was applied onto the dorsolateral region of the hind-limb for 3 min onto an approximately 5 cm² skin area above the sciatic nerve on the lateral thigh of each leg. The US treatment was applied to both legs (right and left leg) at 1 MHz frequency and a power density of 0.5 W/cm² and 1.5 W/cm² in a pulsed mode at 20% duty cycle for 15 days.

Nociceptive tests. Rats in the study groups were subjected to nociceptive tests, hot plate and tail flick tests, on 5th, 19th and 33rd days of cisplatin administration period and once a week during the treatment period. For the tail-flick test, a semi-automatic device with 8 V / 50 W radiant heat source (tail-flick device, May Tic., Ankara, Turkey) was used. The heater source was applied to the lower 1/3 of the tail of all rats. The movement of tails were automatically detected by the device and the heat stimulus was interrupted, the latency for flicking the tails was recorded. In order to prevent permanent damage to the tail, the cut-off time was determined as 10 s. For the hot-plate test, a preheated (55 ± 0.3°C) (circular metal surface (Hot plate device, May Tic., Ankara, Turkey) was used. Response times to the thermal stimulation was recorded, such as the time for licking the hind legs or...
jumping out of the device. The cut-off time was considered as 15 s to prevent any damage. The test was repeated 3 times with an interval of 10 min and the average time was used in data analysis.

**Electrophysiological measurements.** The electrophysiological measurements were performed after 15 days of treatment. The rats were anesthetized using an intraperitoneal injection of ketamine and Xylazine (70:10 mg of ketamine: Xylazine per kg). Afterwards, the left lateral femoral region was shaved and sciatic nerves were exposed through a curvilinear surgical incision. The sciatic nerve was placed onto the in vivo electrodes (Biopac Systems Inc., USA) and a supramaximal electrical stimulation was applied on the sciatic nerve via in vivo distal and proximal electrodes fixed at a distance of 1.1 cm connected to the Biopac MP100 system (Biopac Systems Inc., USA). The recording needle electrodes were placed in the second interosseous cavity of the hind foot and were used to record the CMAP. The ground electrode was placed at the lateral side of the hind foot. The electrical stimulation (0.1 ms, 1 Hz, 7 mV) was applied through the distal and proximal electrodes, respectively, and the resulting CMAPs were recorded from the recording needle electrode and transferred to the computer with the aid of an amplifier. The obtained potentials were analyzed with AcqKnowledge data acquisition and analysis software (Biopac Systems Inc., USA) to record distal and proximal latencies, the duration of CMAP, CMAP peak-to-peak amplitudes and the area under this curve. In addition, MNCV was calculated via the following formula:

\[ \text{MNCV} = \frac{\text{Distance between distal and proximal electrodes}}{\text{(Proximal latency—distal latency)}} \]

After the collection of electrophysiological recordings, the rats were sacrificed and blood samples were collected. The sciatic nerves dissected from the left leg were stored at −80 °C and were used for biochemical measurements and Western blot analysis. The sciatic nerves dissected from the right leg were placed into 10% formalin and were used in the histological analysis.

**Western blot analysis.** For western blot assay, sciatic nerves were homogenized in a RIPA lysis buffer (Catalog # 632424, Merck Millipore, Darmstadt, Germany) including 0.5 M Tris–HCl, pH 7.4, 1.5 M NaCl, 10 μg/ml aprotinin, 1 mM PMSF, 2.5% deoxycholic acid, 10% NP-40, 10 mM EDTA and 1:10 protease inhibitor cocktail (Catalog # P8340, Sigma-Aldrich, USA) was added into the buffer. Then lysates were centrifuged at 15,000 g for 10 min at 4 °C, and the supernatants were collected. Tissue lysates were mixed with sample buffer including 0.5 M Tris–HCl (pH 6.8), glycerol, %10 SDS, bromophenol blue and β-mercaptoethanol, and boiled at 95 °C for 5 min. The protein concentration in lysates was determined by using bicinchoninic acid protein assay kit (Catalog # 23227, ThermoFischer Scientific, USA). An equal amount of protein (20 μg) was taken from each sample and loaded onto polyacrylamide gel (containing 4 and 12% stacking and resolving gels, respectively), subjected to gel electrophoresis and then transferred onto polyvinylidene fluoride membranes (Catalog # IPVH00010, Millipore, Bedford, MA, USA). After blocking, the membranes were incubated with primary antibodies against Parkin (1:1000, Catalog # sc-32282, Santa Cruz, USA), caspase-3 (1:1000, Catalog # sc-56052, Santa Cruz, USA), Bcl-2 (1:1000, Catalog # sc-7382, Santa Cruz, USA) and β-actin (1:1000, Catalog # sc-47778, Santa Cruz, USA) at 4 °C overnight. After washing, the secondary antibody (1:2000, anti-mouse IgG HRP, Catalog # 70765S, Cell Signaling, USA) was applied at room temperature for 2 h, and then the membrane was washed, ECL substrate (Catalog # R705060, BIO-RAD, California, USA) was added and finally membranes were visualized using UVP system (LAB Denmark APS, Denmark) with the same exposure time of 5 min. Measurement of the protein band intensities was performed using ImageJ (MD, USA, 64 bit version) software, as described in the ImageJ user guide. For the quantification of the band intensities, no image processing was performed. The bands corresponding to a specific protein of each experimental group were selected as region of interest and analyzed separately.

**Biochemical analysis.** The malondialdehyde (MDA) levels and superoxide dismutase (SOD) activity in sciatic nerve tissues were measured by the use of appropriate measurement kits (Catalog # 1009060 for MDA and Catalog # 706002 for SOD assay kit, Cayman Chemical, Michigan, USA) according to the manufacturer’s instructions. Likewise, the levels of serum interleukin 1 β (IL-1β) and interleukin 6 (IL-6) levels were determined using appropriate Elisa kits (Elabscience, USA) according to the instructions of the manufacturer (Catalog # E-EL-R0012 for IL-1β and Catalog # E-EL-R0015 for IL-6 Elisa kits).

**Histological analysis.** The dissected right sciatic nerves were fixed in 10% formaldehyde. After the removal of formaldehyde with running water, the tissues were dehydrated through passages from a series of ethanol, infiltrated with paraffin and were embedded in paraffin blocks (Catalog # TK2050066, Tekkim, Turkey) as described previously. 5 μm thick sections were obtained with a rotary microtome (Leica RM 2265, Germany) using a Plasma LS35 Microtome blade. The sections were then stained using Hematoxylin–Eosin, Luxol fast blue (LBF) and Masson’s trichrome staining kits (Atom Scientific, UK) according to the instructions of the manufacturer (Catalog # RSRK26-100 for Hematoxylin-Eosin stain kit, Catalog # RSRK20-100 for Masson's trichrome stain kit and Catalog # RSRK345-100 for LBF stain kit). The stained sections were photographed using an Olympus DP73 microscope (Olympus, Japan). The LBF stained images were further analyzed for the measurements of myelin sheet thickness, axon and myelinated fiber diameter by the use of ImageJ (National Institute of Health, USA) program.

**Statistical analysis.** The data were analyzed with SPSS version 22 for Windows (IBM, USA), and were represented as mean ± standard error of mean (SEM). Statistical analysis of the differences in variance was analyzed using one-way analysis of variance (one-way ANOVA) followed by Tukey’s test as a post-hoc test. A p value equal to or less than 0.05 was accepted as statistically significant (*p < 0.05, **p < 0.01, ***p < 0.001). The degree of significance was symbolized by an asterisks (*) for the comparison of all groups with respect to the control
group; by a double daggers (‡) for the comparison of ultrasound treated groups with respect to the melatonin administered group and by a section ($) for the comparison of 1 MHz 1.5 W/cm² US treated group with respect to the 1 MHz 0.5 W/cm² US treated group.

**Data availability**

The datasets generated in the current study are available from the corresponding author on request.

Received: 9 November 2021; Accepted: 19 April 2022
Published online: 17 May 2022

**References**

1. Park, S. B. et al. Chemotherapy-induced peripheral neurotoxicity: A critical analysis. *CA Cancer J. Clin.* 63, 419–437 (2013).
2. Dumitru, D., Amato, A. A. & Zwarts, M. *Electrodiagnostic Medicine.* 885–899 (Philadelphia: Hanley & Belfus, 2002).
3. Staff, N. P., Grisold, A., Grisold, W. & Windebank, A. J. Chemotherapy-induced peripheral neuropathy: A current review. *Ann. Neurol.* 81, 772–781 (2017).
4. Links, M. & Lewis, C. A review of their clinical pharmacology and therapeutic efficacy. *Chemoprotectants, Drugs.* 57, 293–308 (1999).
5. Pierstorff, E. et al. Prevention of cisplatin-induced hearing loss by extended release fluticasone propionate intracanal implant. *Int. J. Pediatr. Otorhinolaryngol.* 121, 157–163 (2019).
6. Faubel, S. et al. Caspase-1-deficient mice are protected against cisplatin-induced apoptosis and acute tubular necrosis. *Kidney Int.* 66, 2202–2213 (2004).
7. Galea, A. M. & Murray, V. The interaction of cisplatin and analogues with DNA in reconstituted chromatin. *BBA-Gene Struct. Expr.* 1579, 142–152 (2002).
8. Jamieson, E. R. & Lippard, S. J. Structure, recognition, and processing of cisplatin–DNA adducts. *Chem. Rev.* 99, 2467–2498 (1999).
9. Höke, A. Animal models of peripheral neuropathies. *Neurotherapeutics* 9, 262–269 (2012).
10. Abdullah, A. A. & Kabil, S. L. Mitigation of cisplatin-induced peripheral neuropathy by canagliflozin in rats. *Naunyn Schmiedebergs Arch. Pharmacol.* 391, 945–952 (2018).
11. Areti, A., Komirishetty, P., Akuthota, M., Malik, R. A. & Kumar, A. Melatonin prevents mitochondrial dysfunction and promotes neuroprotection by inducing autophagy during oxaliplatin-evoked peripheral neuropathy. *J. Pineal Res.* 62, e12393 (2017).
12. Giordana, S., Usmar, V. D. & Zhang, J. Autophagy as an essential cellular antioxidant pathway in neurodegenerative disease. *Redox Biol.* 2, 82–90 (2014).
13. Yerra, V. G., Gundu, C., Bachewal, P. & Kumar, A. Autophagy: The missing link in diabetic neuropathy?. *Med. Hypotheses* 86, 120–128 (2016).
14. Tsuang, Y. H. et al. Effects of low intensity pulsed ultrasound on rat schwann cells metabolism. *Artif. Organs* 35(4), 373–383 (2010).
15. Wang, X. et al. Low-intensity pulsed ultrasound promotes chondrogenesis of mesenchymal stem cells via regulation of autophagy. *Nutr Cell Res. Ther.* 10, 41 (2019).
16. Creange, A., Barlovatz-Meimon, G. & Gherardi, R. K. Cytokines and peripheral nerve disorders. *Eur. Cytokine Netw.* 8, 145–151 (1997).
17. Pollari, E., Prior, R., Robberecht, W., Damme, P. V. & Bosch, L. V. D. In vivo electrophysiological measurement of compound muscle action potential from the forelimbs in mouse models of motor neuron degeneration. *J. Vis Exp.* 136, 57741 (2018).
18. Bui-Juklakkil, B. et al. Protective effects of platelet-activating factor antagonist ABT-491 on the peripheral nerves in hypoxic ischemia-induced neonatal rat model. *Turkiye Klinikleri J. Med. Sci.* 31, 79–85 (2011).
19. Wang, Y. et al. PINK1/Parkin-mediated mitophagy is activated in cisplatin nephrotoxicity to protect against kidney injury. *Cell Death Dis.* 9, 1113. https://doi.org/10.1038/s41419-018-1152-2 (2018).
20. Skaper, S. D., Floreani, M., Cecconi, M., Facci, L. & Giusti, P. Excitotoxicity, oxidative stress, and the neuroprotective potential of melatonin. *Ann. NY Acad. Sci.* 900, 107–118 (1999).
21. Carriel, V., Garzon, I., Alaminos, M. & Campos, A. Evaluation of myelin sheath and collagen reorganization pattern in a model of peripheral nerve regeneration using an integrated histochemical approach. *Histochem. Cell Biol.* 136, 709–717 (2011).
22. Turedi, S., Yulug, E., Alver, A., Bodur, A. & Ince, I. A morphological and biochemical evaluation of the effects of quercetin on experimental sciatic nerve damage in rats. *Exp. Ther. Med.* 15, 3215–3224 (2018).
23. Grisold, W., Cavaletti, G. & Windebank, A. J. Peripheral neuropathies from chemotherapeutics and targeted agents: diagnosis, treatment, and prevention. *Neurooncology* 14, 45–54 (2012).
24. Authier, N., Gillet, J. P., Fialip, J., Eschalier, A. & Coudore, F. An animal model of nociceptive peripheral neuropathy following repeated cisplatin injections. *Exp. Neurol.* 182(1), 12–20 (2003).
25. Nozaki-Taguchi, N., Chaplan, S. R., Higueria, E. S., Ajakwe, R. C. & Yaksh, T. L. Vincristine-induced alldynia in the rat. *Pain* 93, 69–76 (2001).
26. Paolicchi, A. et al. Glutamate transpeptidase catalyses the extracellular detoxification of cisplatin in a human cell line derived from the proximal convoluted tubule of the kidney. *Eur. J. Cancer.* 39, 996–1003 (2002).
27. Townsend, D. M., Tew, K. D., Lin, H., King, J. B. & Hanigan, M. H. Role of glutathione-S- transferase Pi in cisplatin-induced nephrotoxicity. *Biomed. Pharmacother.* 73, 79–85 (2009).
28. Ahmad, N. et al. Gabapentin and its salicylic acid derivative alleviate alldynia and hypoalgesia in a cisplatin-induced neuro- pathic pain model. *Eur. J. Pharmacol.* 814, 302–312 (2017).
29. Han, F. Y., Wyse, B. D. & Smith, M. T. Optimization and pharmacological characterization of a refined cisplatin-induced rat model of peripheral neuropathic pain. *Behav. Pharmacol.* 25(8), 732–740 (2014).
30. Daeschler, S. C. et al. Ultrasound and shock-wave stimulation to promote axonal regeneration following nerve surgery: a systematic review and meta-analysis of preclinical studies. *Sci. Rep.* 8, 3168. https://doi.org/10.1038/s41598-018-21540-5 (2018).
31. Ahmed, O. F., Elkarbotly, A. M., Taha, N. & Bekheet, A. R. Treatment of mild to moderate carpal tunnel syndrome in patients with diabetic neuropathy using low level laser therapy versus ultrasound controlled comparative study. *BBA Clin.* 8, 43–47 (2017).
32. Okan, F. U. et al. New treatment alternatives in the ulnar neuropathy at the elbow: ultrasound and low-level laser therapy. *Acta Neurol. Belg.* 115, 355–360 (2015).
33. Tankisi, H., Otto, M., Pugdahl, K., Johnsen, B. & Fuglsang-Frederiksen, A. Correlation between compound muscle action potential amplitude and duration in axonal and demyelinating polyneuropathy. *Clin. Neurophysiol.* 123, 2099–2105 (2012).
34. Chen, W. Z., Qiao, H., Zhou, W., Wu, J. & Wang, Z. B. Upgraded nerve growth factor expression induced by low-intensity continuous-wave ultrasound accelerates regeneration of neurotactically injured sciatic nerve in rats. *Ultrasound Med. & Biol.* 36(7), 1109–1117 (2010).
35. Jiang, W. et al. Low-intensity pulsed ultrasound treatment improved the rate of autograft peripheral nerve regeneration in rat. *Sci. Rep.* 6, 22773 (2016).
36. Sovereign, A. et al. Assay of therapeutic ultrasound induced-antinociception in experimental trigeminal neuropathic pain. J. Neurosci. Res. 90(8), 1639–1645 (2012).
37. Chen, T. T., Lan, T. H. & Yang, F. Y. Low-intensity pulsed ultrasound attenuates LPS-induced neuroinflammation and memory impairment by modulation of TLR4/NF-κB signaling and CREB/BDNF expression. Cereb. Cortex 29, 1430–1438 (2019).
38. Raso, V. V. M., Barbieri, C. H., Mazzer, N. & Fasan, V. S. Can therapeutic ultrasound influence the regeneration of peripheral nerves? J. Neurosci. Methods 142, 185–192 (2005).
39. Al-Moudhiri, M. S. et al. The effect of curcumin on oxaliplatin and cisplatin neurotoxicity in rats: some behavioral, biochemical, and histopathological studies. J. Med. Toxicol. 9, 23–33 (2013).
40. Areti, A., Yerra, V. G., Naidu, V. G. M. & Kumar, A. Oxidative stress and nerve damage: Role in chemotherapy-induced peripheral neuropathy. Redox Biol 2, 289–295 (2014).
41. Rosse, F. Extrinsic cellular and molecular mediators of peripheral axonal regeneration. Cell Tissue Res. 349(1), 5–14 (2012).
42. Ruohonen, S. et al. Cytokine responses during chronic denervation. J. Neuroinflammation. 2, 26 (2005).
43. Chang, J. W., Wu, M. T., Song, W. S. & Yang, F. Y. Ultrasound stimulation suppresses LPS-induced proinflammatory responses by regulating NF-κB and CREB activation in microglial cells. Cereb. Cortex 30, 4597–4606 (2020).
44. Wang, F. et al. Low-intensity focused ultrasound stimulation ameliorates working memory dysfunctions in vascular dementia rats via improving neuronal environment. Front. Aging Neurosci. 14, 814560 (2022).
45. Ito, A. et al. Ultrasound therapy with optimal intensity facilitates peripheral nerve regeneration in rats through suppression of pro-inflammatory and nerve growth inhibitor gene expression. PLoS ONE 15(6), e0234691 (2020).
46. Zhua, Y. et al. Interleukin-6: an emerging regulator of pathological pain. J. Neuroinflammation. 13, 141. https://doi.org/10.1186/s12974-016-0607-6 (2016).
47. Vasaikar, N. et al. D-pinitol attenuates cisplatin-induced nephrotoxicity in rats: Impact on proinflammatory cytokines. Chem. Biol. Interact. 290, 6–11 (2018).
48. Park, S. A. et al. Bcl-2 blocks cisplatin-induced apoptosis by suppression of ERK-mediated p53 accumulation in B104 cells. Mol. Brain Res. 93, 18–26 (2001).
49. Brozovic, A., Ristov, A. A. & Osmak, M. The relationship between cisplatin-induced reactive oxygen species, glutathione, and BCL-2 and resistance to cisplatin. Crit. Rev. Toxicol. 40, 347–359 (2010).
50. Adams, J. M. & Cory, S. Life or death decisions by the Bcl-2 family. Trends. Biochem. Sci. 26, 61–66. https://doi.org/10.1016/s0968-0004(00)01740-0 (2001).
51. Canta, A., Pozzi, E. & Carozzi, V. A. Mitochondrial dysfunction in chemotherapy-induced peripheral neuropathy (CIPN). Toxics. 3(2), 198–223 (2015).
52. Zhang, Y. et al. PTEN-induced putative kinase 1 (PINK1)/Parkin- mediated mitophagy protects PC12 cells against cisplatin-induced neurotoxicity. Med. Sci. Monit. 25, 8797–8806 (2019).
53. Bolanos, J. P., Almeida, A. & Moncada, S. Glycogen: A bioenergetic or a survival pathway?. Trends Biochem. 35, 45–49 (2010).
54. Kaya, Y. et al. Comparison of the beneficial effect of melatonin on recovery after cut and crush sciatic nerve injury: a combined study using functional, electrophysiological, biochemical, and electron microscopic analyses. Childs Nerv. Syst. 29, 389–401 (2013).
55. Galley, H. F., McCormick, B., Wilson, K. L., Lowes, D. A. & Torsney, C. Melatonin limits paclitaxel-induced mitochondrial dysfunction in vitro and protects against paclitaxel-induced neurotoxic pain in the rat. J. Pineal Res. 63, 12444. https://doi.org/10.1111/jpi.12444 (2017).

Acknowledgements
The authors would like to thank to Prof. Mehmet Dincer Bilgin for his guidance and support during the US treatments.

Author contributions
B.B.Y. and O.B.G. designed the study. B.B.Y. carried out the experiments. F.B.S. and H.F.Y. performed histological analysis and measurements. B.B.Y., H.F.Y. and O.B.G. analyzed and interpreted the data. B.B.Y. and O.B.G. prepared the final manuscript. All authors have revised and edited the final manuscript.

Funding
This study was supported by the Aydın Adnan Menderes University Scientific Research Fund (Grant Number TPF-19015).

Competing interests
The authors declare no competing interests.

Additional information
Supplementary Information The online version contains supplementary material available at https://doi.org/10.1038/s41598-022-11978-z.

Correspondence and requests for materials should be addressed to O.B.-G.

Reprints and permissions information is available at www.nature.com/reprints.

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2022